

30th May 2006

## **CogState Announces First Contract with GlaxoSmithKline**

### **Key points:**

- **CogState technology to be used for the first time by GlaxoSmithKline in a phase I clinical trial**
- **CogState continuing to expand its customer base within large pharmaceutical companies**

CogState Ltd (ASX:CGS) announced today that it has signed an agreement with GlaxoSmithKline Ltd (GSK) to provide its cognitive testing services in a phase I clinical trial.

GSK is one of the largest pharmaceutical companies in the world and conducts a significant number of clinical trials each year. This trial is the first time that GSK has used CogState's technology to measure changes in cognition of its clinical trial participants.

CogState technology is currently being used by other major pharmaceutical companies such as Pfizer, Organon USA and Alza Corporation (part of the Johnson & Johnson group) in their clinical trials.

Following recent announcements, the total value of CogState's contracted future revenue exceeds A\$2.3m. Contracted future revenues are revenue amounts to be recognised in coming periods, from signed agreements currently in place. Of the A\$2.3m in contracted future revenue, CogState expects A\$1.6m to be recognised before 30 June 2007. CogState anticipates signing additional contracts with both existing and new customers over coming months that will increase total revenue for the year to 30 June 2007.

CogState's CEO, Brad O'Connor, commented "CogState is focussed on expanding the number of customers using our technology within their clinical trials. Collaborations such as this are important steps in our path towards profitability."